Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 2

2264 - Prediction of S-1 adjuvant chemotherapy efficacy in Stage II/III gastric cancer treatment based on comprehensive gene expression analysis


29 Sep 2019


Poster Display session 2


Tumour Site

Gastric Cancer


Masanori Terashima


Annals of Oncology (2019) 30 (suppl_5): v253-v324. 10.1093/annonc/mdz247


M. Terashima1, K. Nakamura1, K. Hatakeyama2, K. Furukawa1, K. Fujiya1, S. kamiya1, M. Hikage1, Y. Tanizawa1, E. Bando1, K. Oshima2, K. Urakami3, N. Machida4, H. Yasui4, K. Yamaguchi5

Author affiliations

  • 1 Division Of Gastric Surgery, Shizuoka Cancer Center, 411-8777 - Shizuoka/JP
  • 2 Medical Genetics Division, Shizuoka Cancer Center Research Institute, 411-8777 - Shizuoka/JP
  • 3 Cancer Diagnostics Research Division, Shizuoka Cancer Center Research Institute, 411-8777 - Shizuoka/JP
  • 4 Division Of Gastrointestinal Oncology, Shizuoka Cancer Center, 411-8777 - Shizuoka/JP
  • 5 Research Institute, Shizuoka Cancer Center, 411-8777 - Shizuoka/JP


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 2264


Studies to identify predictive biomarkers of adjuvant chemotherapy with S-1 after gastrectomy in Stage II/III gastric cancer patients have been done; however, more clarity and understanding are needed. Our aim in the present study was to identify biomarkers predicting benefit due to S-1 adjuvant chemotherapy using comprehensive gene expression analysis.


We retrospectively analyzed 102 patients receiving adjuvant chemotherapy with S-1 and 46 patients not receiving S-1 adjuvant chemotherapy after gastrectomy for gastric cancer treatment between January 2014 and December 2016. Hierarchical clustering analysis was performed based on the gene expression data obtained using DNA microarrays. Differentially expressed genes (DEGs) were identified using thresholds of absolute fold changes (FCs) of > 4.0 and a false discovery rate (FDR) P value of < 0.01. Gene Ontology (GO) analysis and GO network visualization were performed using the ClueGO app in Cytoscape.


Hierarchical clustering analysis in patients treated with S-1 adjuvant chemotherapy revealed two clusters with favorable and unfavorable survival outcomes. We identified 147 upregulated DEGs and 192 downregulated DEGs in the favorable outcome group. GO analysis to identify significantly upregulated genes showed enrichment in immune-related genes and GO terms. Upregulation of these immune-related genes was not associated with survival in patients not receiving S-1 adjuvant chemotherapy.


The upregulation and enrichment of immune-related genes and GO terms may be a predictive biomarker in patients who would benefit from adjuvant S-1 chemotherapy to treat Stage II/III gastric cancer.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.


Has not received any funding.


M. Terashima: Honoraria (self): Taiho; Honoraria (self): Chugai; Honoraria (self): Yakult; Honoraria (self): ONo; Honoraria (self): BMS; Honoraria (self): Eli-Lilly; Honoraria (self): Takeda; Honoraria (self): Daiichi-Sankyo; Honoraria (self): Kyowa Hakko Kirin; Honoraria (self): Nihon Kayaku; Honoraria (self): Pfizer. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.